Sunday 18 October 2026
Export FHTX’s income statement to Excel — free account
Foghorn Therapeutics Inc.
FHTX Healthcare Biotechnology
Foghorn Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 36.8% from fiscal 2024. In the quarter to June 2026, revenue grew 112.7%, EPS grew 64.3% and free cash flow grew 14.9%, each against the same quarter a year earlier.
1.85
0.04
−2.12%
Follow FHTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
12.57 | 11.00 | 11.78 | 9.38 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(16.34) | (15.27) | (13.16) | (19.32) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.98 | 6.47 | 5.93 | 5.36 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.66) | (2.32) | (1.92) | (2.34) | |
EV/FCF |
(1.65) | (2.32) | (1.91) | (2.34) | |
Quick Ratio |
2.13 | 2.68 | 2.87 | 3.31 | |
Current Ratio |
2.16 | 2.73 | 2.92 | 3.36 | |
Net Debt/EBITDA |
10.08 | 6.85 | 8.51 | 18.23 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.10 | 0.13 | 0.12 | 0.17 | |
Operating CF/Net income |
1.19 | 1.03 | 1.27 | 2.48 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.13 | |
Research and Development Expense of Revenue |
245.33% | 238.41% | 558.89% | 115.25% | |
Selling, General and Administrative Expense of Revenue |
81.59% | 73.50% | 201.44% | 39.53% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
33.52% | 24.23% | 72.94% | 15.87% | |
Graham Net Nets |
(0.36) | (0.42) | (0.33) | (0.33) | |
Graham Number |
6.01 | 6.73 | 5.36 | 5.03 | |
Earnings Yield |
(23.11%) | (21.67%) | (24.27%) | (20.08%) | |
Free Cash Flow Yield |
(28.84%) | (25.33%) | (26.31%) | (24.46%) | |
Revenue per Share |
0.13 | 0.15 | 0.05 | 0.23 | |
Operating CF per Share |
(0.30) | (0.35) | (0.36) | (0.25) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.30) | (0.35) | (0.36) | (0.25) | |
Cash per Share |
2.88 | 2.54 | 2.66 | 2.37 | |
Shareholders Equity per Share |
(1.42) | (1.72) | (1.10) | (1.15) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.42) | (1.72) | (1.10) | (1.15) | |
Free Cash Flow |
(18.86) | (22.27) | (25.27) | (17.89) | |
Working Capital |
99.03 | 103.50 | 123.66 | 119.47 | |
Capital Expenditures |
0.00 | 0.00 | — | (0.05) | |
Net Current Asset Value |
(110.50) | (143.37) | (110.51) | (114.39) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
3.33 | 4.03 | 3.69 | 3.26 | |
Average Assets |
256.67 | 241.04 | 240.43 | 214.81 | |
Average Common Equity |
(58.97) | (77.01) | (69.03) | (78.85) |
Columns are period end dates